 WORCESTER, Mass., Nov. 06, 2020 GLOBE NEWSWIRE -- Mustang Bio, Inc. Mustang NASDAQ: MBIO, a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2020. 